TABLE 3.
SARS-CoV-2 nasopharyngeal viral load in log10 copies/reaction according to demographic and clinical characteristics of hospitalized kidney transplant recipients (N = 39)
| n | Nasopharyngeal maximal viral load | P | |
|---|---|---|---|
| COVID-19 severity | .23 | ||
| Nonsevere disease | 21 | 5.17 [3.80-6.61] | |
| Severe disease | 18 | 6.38 [4.88-7.21] | |
| Recipient age, y | .70 | ||
| <60 | 24 | 5.26 [3.42-6.92] | |
| ≥60 | 15 | 5.88 [4.43-7.04] | |
| Sex | .05 | ||
| Female | 8 | 7.34 [5.74-8.02] | |
| Male | 31 | 5.17 [4.32-6.63] | |
| BMI, kg/m2 | .08 | ||
| <30 | 20 | 6.50 [5.10-7.32] | |
| ≥30 | 19 | 4.90 [3.43-6.42] | |
| Obstructive sleep apnea | .57 | ||
| No | 32 | 5.81 [4.71-7.14] | |
| Yes | 7 | 4.44 [3.50-4.44] | |
| Cardiovascular disease | .84 | ||
| No | 23 | 6.01 [4.88-6.84] | |
| Yes | 16 | 5.04 [3.80-7.50] | |
| Respiratory disease | .31 | ||
| No | 24 | 6.26 [4.62-7.28] | |
| Yes | 15 | 4.90 [4.32-6.70] | |
| Diabetes | .11 | ||
| No | 21 | 6.01 [4.90-7.55] | |
| Yes | 18 | 5.04 [3.24-6.45] | |
| Hypertension | .84 | ||
| No | 7 | 5.17 [4.35-6.82] | |
| Yes | 32 | 5.81 [4.37-7.14] | |
| RAAS inhibitor | .17 | ||
| No | 25 | 6.38 [4.90-7.11] | |
| Yes | 14 | 6.88 [3.34-6.53] | |
| Immunosuppressive induction therapy | .20 | ||
| Anti-thymocyte globulin | 18 | 6.38 [2.59-7.61] | |
| Anti-CD25 | 18 | 5.17 [3.96-6.45] | |
| No induction | 3 | 4.90 [3.85-6.07] | |
| Immunosuppressive maintenance therapy | |||
| CNI | .71 | ||
| No | 5 | 4.90 [4.42-7.76] | |
| Yes | 34 | 5.81 [3.96-7.00] | |
| MMF/MPA | .15 | ||
| No | 6 | 7.08 [6.34-7.81] | |
| Yes | 33 | 5.17 [4.21-6.66] | |
| mTOR | .92 | ||
| No | 33 | 5.61 [4.21-7.02] | |
| Yes | 6 | 5.92 [4.54-7.16] | |
| Steroids | .03 | ||
| No | 17 | 4.87 [3.05-6.38] | |
| Yes | 22 | 6.50 [5.17-7.53] | |
| Clinical symptoms | |||
| Dyspnea | .23 | ||
| No | 12 | 4.79 [2.73-6.71] | |
| Yes | 27 | 6.15 [4.88-7.17] | |
| Diarrhea | .02 | ||
| No | 9 | 6.93 [6.38-7.41] | |
| Yes | 30 | 5.17 [3.80-7.83] | |
| Positive RNAemia | .35 | ||
| No | 18 | 5.17 [4.26-6.88] | |
| Yes | 9 | 6.61 [5.26-7.24] | |
Nasopharyngeal maximal viral load is presented as median (interquartile range).
BMI, body mass index; CNI, calcineurin inhibitor; COVID-19, coronavirus disease 2019; MMF, mycophenolate mofetil; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin; RAAS, renin-angiotensin-aldosterone system; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.